ASIAN JOURNAL OF MEDICAL SCIENCES

Characteristics of Ankylosing spondylitis patients in Kurdistan region of Iraq



Mahir Sadullah Saeed¹, Mohammed Tahir Rasool²

¹Physician, Specialized Centre of Rheumatic Diseases and Medical Rehabilitation, Duhok General Directorate of Health, 2Rheumatologist, FRCP, Assistant Professor of Rheumatology, Department of Medicine, College of Medicine, University of Duhok, Kurdistan Region, Duhok, Iraq

Submission: 02-08-2022

Revision: 29-09-2022

Publication: 01-11-2022

Access this article online

http://nepjol.info/index.php/AJMS

DOI: 10.3126/ajms.v13i11.47137

Copyright (c) 2022 Asian Journal of

This work is licensed under a Creative

E-ISSN: 2091-0576

P-ISSN: 2467-9100

Medical Sciences

Website:

ABSTRACT

Background: Ankylosing spondylitis (AS) affects predominantly the axial skeleton and causes inflammatory low back pain. Aims and Objectives: We aimed to explore clinical characteristics of AS patients in Iragi Kurdistan. Materials and Methods: In this crosssectional study, the patients who attended a rheumatic disease center in Kurdistan Region of Iraq in 2022 were screened for the diagnosis of AS. Results: The mean age of the patients was 38.31 (17-65 years old) and most were Middle age and males (93.07%; male: female ratio: 13.43:1). The patients were normal sleepers (61.39%), short sleepers (28.71%), and long sleepers (9.90%). The patients were most physically active through walking. The age at symptoms onset of patients was 22.61 years (7-56 years). The patient's disease was diagnosed at the mean value of 29.56 years. The median gap of diagnosis was 5 years. The patients had different characteristics; peripheral arthritis (56.44%), sacroiliitis (bilateral: 91.09%), tenosynovitis (14.85%), plantar fasciitis (45.54%), achilles tendinitis (17.82%), anterior uveitis (23.76%), positive human leukocyte antigen-B27 (88.40%), and spinal involvement (94.06%). Most patients received treatment (89.11%) including received biological treatment (53.47%) followed by multiple treatments (29.70%) and nonsteroidal (4.95%) and only 0.99% (one patient) used physical therapy. The patients with normal sleepers and physically active and without extra-articular manifestations of AS had better disease severity and function compared to short sleepers and nonphysically active. Conclusion: A AS patients have escalating disease severity and function patients in this region. The disease severity and function were associated with healthy lifestyles such as sleeping and physical activity.



Key words: Ankylosing spondylitis; Musculoskeletal symptoms; Disease severity; Disease function

INTRODUCTION

Ankylosing spondylitis (AS) is considered a prototype of a group of chronic inflammatory diseases called spondyloarthritides.¹ This disease affects predominantly the axial skeleton and causes inflammatory low back pain. The main joins involved in the AS are sacroiliac joints. Peripheral arthritis, enthesitis, and tenosynovitis are musculoskeletal manifestations of patients with AS.² The following are extra-articular manifestations of AS; uveitis, inflammatory bowel disease, cardiac abnormalities, and apical fibrosis of the lungs.^{3,4}

The diagnosis of AS is usually delayed and this delayed diagnosis is a gap of several years between the onset of symptoms and the actual diagnosis. The delayed diagnosis could be due to a low level of awareness among nonrheumatologists about AS, the high prevalence of chronic low back pain in the population, and the late appearance of radiological evidence of sacroiliitis in the disease course.⁵ The involvement of ankylosing in the spine leads to structural and functional impairments and a decrease in quality of life.6

There are few studies conducted on the characteristics of AS in the Middle East.7-11 For example, a study conducted

Address for Correspondence:

Dr. Mahir Sadullah Saeed, Physician, Specialized Centre of Rheumatic Diseases and Medical Rehabilitation, Duhok General Directorate of Health, Kurdistan - 42001, Dihok, Iraq. Mobile: +964 750 469 6277. E-mail: mahirsadullah@gmail.com

in Qatar reported that the mean age of the patients was 25.9 years, and at diagnosis at 32.3 years. The average delay in the diagnosis was 6.4 years. The disease was most prevalent among males (male: female ratio: 5.2:1). Human leukocyte antigen (HLA)-B27 was positive in the majority of patients (80.7%). Different disease features were reported as well.⁷ The mean value of disease severity and function was 3.3 and 2.9, respectively.

Until now, there is only one study about AS in this region. The study aimed to explore the prevalence of HLA-B*27 among the healthy Kurdish population and in patients with AS⁹ along with another conducted in Baghdad.¹²

Aims and objectives

In this study, we aimed to explore the clinical characteristics of AS patients in the Kurdistan Region of Iraq/Duhok governorate.

MATERIALS AND METHODS

Study design and sampling

In this cross-sectional study, the patients who attended the Specialized Centre of Rheumatic Diseases and Medical Rehabilitation were screened for the diagnosis of AS. The patients who were diagnosed with AS by a rheumatologist were included in this study. All patients were screened by a rheumatologist for the eligibility criteria. The patients of both genders without age restriction were eligible for this study irrespective of extra-articular manifestations of AS and sociodemographic aspects. The study was pre-approved by the Institutional Ethics Committee for the final permission. The patients with other rheumatic diseases were not included in this study. The patients who were diagnosed with AS and had other rheumatic diseases were eligible for this study.

Diagnosis and measures

The diagnosis of the study was established by the Spondylo Arthritis International Society (ASAS) classification criteria for axial spondyloarthritis.¹³

Disease severity

The severity of the diseases was assessed using "The Bath AS Disease Activity Index" (BASDAI).¹⁴ The BASDAI scale is used to assess the disease severity in patients with AS. It is a validated diagnostic test. The scale is a quick and simple index to determine the effectiveness of the current drug therapy for patients suffering from AS. The BASDAI has six quarrions for the five major symptoms of the disease; fatigue, spinal pain, joint pain or swelling, areas of localized tenderness, and morning stiffness duration and severity. The questions are rated between 0

and 10, where 0 means that there is no problem and 10 that the problem is severe. The formula for calculation of BASDAI score is

BASDAI score = (Q1 + Q2 + Q3 + Q4 + (Q5 + Q6)/2)/5,

Where Q means the points for each question.

The average of questions 5 and 6 was used because they both relate to the same symptom – morning stiffness. After performing all of the calculations, the total BASDAI score can range from 0 to 10 points. A higher score means worse disease severity.

Disease function

The function of AS was measured using the Bath AS Functional Index (BASFI). The scale is a set of ten questions designed to determine the degree of functional limitation in patients with AS. The first eight questions are about everyday tasks and are dependent on functional anatomy. The functional anatomy is bending, reaching, changing position, standing, turning, and climbing steps with or without rail. The final two questions assess the ability of patients in coping with everyday life. The items are rated between 0 and 10. On this scale, zero means no functional impairments, and 10 means maximal impairment. The scores of questions are added together and divided by 10 to obtain the total score of the function. The mean of the individual scores is calculated to get the overall mean score of the function. A higher score indicates a higher degree of functional limitations.¹⁵

The extra-articular manifestations of AS in the patients diagnosed with AS were recorded in a pre-designed questionnaire. The extra-articular manifestations of AS in the patients were obtained from their medical records registered in the center.

Statistical analysis

Categorical and continuous values were expressed as frequency (percentage) and mean (SD). Descriptive statistics were used to summarize the demographic, epidemiological, radiographic, and other clinical characteristics of the patients. The prevalence of extraarticular manifestations of AS among patients with AS was determined in number and percentage. Disease severity and function of patients with AS among patients with different severity were examined in an independent t-test or analysis of Variance one-way as appropriate. Controlling factors to function and disease of patients with AS were examined in standard least square with effect leverage. The significant level of difference was determined by P<0.05. The statistical calculations were performed in JMP pro 14.3.0.

Ethical approval

The ethical approval of this study was taken from the Research Ethics Committee registered as the reference number 1342022-2-9 on April 13, 2022. The confidentiality of the personal information of the patients was protected throughout the study steps. The right of the patients to participate was protected in the study.

RESULTS

The mean age of the patients was 38.31 and mostly young and middle ages; 40 years and older (45.55%) compared to 25-39 years old (44.55%) and 17-24 years old (9.90%). Most of the patients were males (93.07%). Only seven patients were females (6.93%). The male: female ratio was 13.43:1. Most of the patients were normal sleepers (61.39%) followed by short sleepers (28.71%) and long sleepers (9.90%). We found that most of the patients were physically active through walking (95.05%) for 45-119 min/day (31.68%) and longer (34.65%) and few focused on moderate physical activity (9.90%) for 1-44 min (1.98%) and 45-119 min/day (5.94%) and only four patients did the vigorous physical activity. Close to two-thirds were from urban areas (74.26%) and the majority were Kurdish (99.01%). Only one patient was Chaldean (Table 1).

The age at symptoms onset of patients was 22.61 years between 7 and 56 years. The age at symptoms of most of the patients was between 10 and 39 years. The patients' disease was diagnosed at the mean value of 29.56 years and in different age groups. The age at diagnosis of most patients was after 5 years. The patients had different extra-articular manifestations of AS; peripheral arthritis (56.44%), sacroiliitis (bilateral: 91.09%), tenosynovitis (14.85%), plantar fasciitis (45.54%), achilles tendinitis (17.82%), anterior uveitis (23.76%), HLA-B27 (88.40%), and spinal involvement (94.06%). Most patients received the treatment (89.11%). The patients received different treatments, mostly received biological treatment (53.47%) followed by multiple treatments (29.70%) and nonsteroidal (4.95%) and only 0.99% (one patient) used physical therapy. The median gap of diagnosis was 5 years (Table 2).

The study showed that the normal sleepers had a better function of diseases compared to short sleepers, 3.35 versus 5.32 (P=0.0039). In addition, those patients who did moderate physical activity had a better function of disease compared to those who did not do moderate physical activity, 1.28 versus 4.32; P=0.0006. The function of the disease was improved by increasing the duration of moderate physical activity and vigorous physical activity.

Table 1: General information of the patients with ankylosing spondylitis

General information (n=101)	Frequency distribution, n (%)		
Age (17–65 years)	Mean: 38.31 (SD: 11.02)		
15–24	10 (9.90)		
25–34	31 (30.69)		
35-44	31 (30.69)		
45–54	22 (21.78)		
55-65	7 (6.93)		
Gender	()		
Male	94 (93.07)		
Female	7 (6.93)		
Sleeping	()		
Long sleeper	10 (9.90)		
Normal sleeper	62 (61.39)		
Short sleeper	29 (28.71)		
Walking			
No	5 (4.95)		
Yes	96 (95.05)		
Walking category			
No walking	5 (4.95)		
1–44 min	29 (28.71)		
45–119 min	32 (31.68)		
120 and longer	35 (34.65)		
Moderate PA			
No	91 (90.10)		
Yes	10 (9.90)		
Moderate PA category			
No moderate PA	91 (90.10)		
1–44 min	2 (1.98)		
45–119 min	6 (5.94)		
120 and longer	2 (1.98)		
Residency	(),		
Rural	26 (25.74)		
Urban	75 (74.26)		
Ethnicity			
Kurdish	100 (99.01)		
Chaldean	1 (0.99)		
A. Physical activity SD. Standard doviation			

The study showed that the patients who had symptoms at earlier stages of life had better function compared to those patients who had symptoms at older ages. A similar pattern was found for the age at diagnosis (Table 3).

The study showed that the patients with normal sleepers had better disease severity (3.61) compared to short sleepers (6.18) and long sleepers (5.13; P<0.0001). In addition, the patients who did moderate physical activity and live in urban areas had better disease severity; 2.65 and 3.97 compared to those patients who did not do moderate physical activity and lived in rural areas; 4.52 and 5.39, respectively. The disease severity was not statistically significant in patients of different gender, walkers, and non-walkers, and at different ages at symptoms and diagnosis (Table 3).

The study showed that the patients without peripheral arthritis had better disease severity and function compared

Table 2: Medical information of patients withankylosing spondylitis		
Medical information (n=101)	Frequency distribution, n (%)	
Age at symptoms (7–56 years) 0–9 10–19 20–29 30–39 40–49 50–59 Age diagnosis 10–14	22.61 (8.14) 4 (3.96) 39 (38.61) 42 (41.58) 14 (13.86) 1 (0.99) 1 (0.99) 29.56 (10.32) 4 (3.96)	
15-19 $20-24$ $25-29$ $30-34$ $35-39$ $40-44$ $45-49$ $50-54$ $55-59$ $60-64$	11 (10.89) 15 (14.85) 25 (24.75) 14 (13.86) 16 (15.84) 7 (6.93) 6 (5.94) 1 (0.99) 1 (0.99) 1 (0.99)	
(IQR) Peripheral arthritis No/Yes Sacroilliitis None	5 (7) 44/57 (43.56/56.44) 6 (5.94)	
Unilateral Bilateral Tenosynovitis	3 (2.97) 92 (91.09)	
Plantar fasciitis No/Yes Achilles tendinitis	55/46 (54.46/45.54)	
No/Yes Anterior uveitis No/Yes	83/18 (82.18/17.82) 77/24 (76.24/23.76)	
No Yes Not done	8 (11.60) 61 (88.40) 32 (31.68)	
No/Yes Treatment No treatment	6/95 (5.94/94.06) 11 (10.89)	
Biological Non-steroidal Physical therapy Multi-therapy ILA: Human leukocyte antigen. IQR: Interquartile	54 (53.47) 5 (4.95) 1 (0.99) 30 (29.70)	

to those patients affected by peripheral arthritis. The patients with spinal involvement had worse disease severity (4.54) compared to the patients without spinal involvement (1.08; P=0.0008). The patients with achilles tendinitis had better disease function (2.13) compared to the patients without achilles tendinitis (4.17; P=0.0042). However, the patients with spinal involvement had worse disease severity and function compared to those patients without spinal involvement, 4.54 versus 1.08; P=0.0008 and 4.19 versus 1.37; P=0.0125, respectively (Table 4).

The study showed that worse disease severity is the only factor that predicts the worse disease function in patients with AS. Other factors did not predict the disease function in patients with AS (Table 5 and Figure 1).

The study showed that living in rural areas, short sleeping, and having spinal involvement are the main factors that predict the worse disease severity in patients with AS. Other general and medical factors did not predict the disease severity in patients with AS (Table 6 and Figure 2).

DISCUSSION

This study showed that most of the patients with AS were old males, normal sleepers, and were physically active through walking. The age at symptoms of the patients was wide and the disease was later diagnosed. The patients had different manifestations of AS and the most prevalent ones were bilateral sacroiliitis, peripheral arthritis, plantar fasciitis, HLA-B27, and spinal involvement. The study showed that the patients with normal sleepers, living in urban areas, and doing moderate physical activity had better disease severity and function. In addition, the patients who had symptoms at earlier stages of life and were diagnosed earlier had better disease function. The patients with spinal involvement had worse disease severity and function compared to the patients without spinal involvement. The worse disease severity is the only factor that predicts the worse disease function in patients with AS. However, living in rural areas, short sleeping, and having spinal involvement are the main factors that predict the worse disease severity in patients with AS.

The studies conducted in other regions of the Middle East and the world have shown that most of the patients are young and middle ages and male. For example, a study conducted in Qatar reported that the mean age of the patients with AS was 25.9 years compared to 38.31 years in our study. The male-to-female ratio was 5.2:1 compared to the highly different one in our study; the male: female ratio: was 13.43:1.⁷ A study conducted in Baghdad reported similar findings in terms of age (36.89 years) with a 10.11:1 male: female ratio¹² and that one conducted in the Kurdistan Region of Iraq.⁹ The male: female ratio reported in this study is a little bit different, despite the disease being more prevalent among males compared to females.^{8,10,11,16} The male: female ratio was 2.8:1 in Saudi Arabia,⁸ 8.1:1 in Jordan,¹⁰ and 8.6:1 in Korea.¹⁷

In addition, the disease was diagnosed late in this study. The diagnosis of AS is lately diagnosed in other countries as well.^{7,11} Most patients with AS are males. Another

$\begin{tabular}{ c c c c } \hline begin{tabular}{ c c c } \hline begin{tabular}{ c c c } \hline begin{tabular}{ c c c c } \hline begin{tabular}{ c c c c } \hline begin{tabular}{ c c c c c c } \hline begin{tabular}{ c c c c c c c } \hline begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Charactoristics				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	onaracteristics	Moon (SD)		Moon (SD)	P
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Mean (SD)	٢	Mean (SD)	P
Gender Gender <thgen< td="" thd<=""><td>BASDAI, range</td><td>4.33 (2.49), 0–9.3</td><td></td><td>4.02 (2.70), 0–9.7</td><td></td></thgen<>	BASDAI, range	4.33 (2.49), 0–9.3		4.02 (2.70), 0–9.7	
Female $0.07 (0.55)$ 0.0836 $4.24 (224)$ 0.8207 Male $4.25 (2.53)$ $4.00 (2.71)$ Short sleeper $6.18 (1.60)$ 0.0005 $5.32 (2.5)$ 0.0039 Normal sleeper $5.13 (1.77)$ $4.36 (2.72)$ Walking 0 $2.96 (2.20)$ 0.2082 $3.12 (3.34)$ 0.4489 Yes $4.41 (2.50)$ 0.2082 $3.12 (3.34)$ 0.4489 Yes $4.41 (2.50)$ 0.2828 $3.12 (3.34)$ 0.5823 $1-44 \min$ $4.71 (2.28)$ 0.2828 $3.12 (3.34)$ 0.5823 $1-44 \min$ $4.71 (2.28)$ 0.2828 $3.12 (3.34)$ 0.5823 $1-44 \min$ $4.71 (2.28)$ 0.2828 $3.12 (3.24)$ 0.5823 $1-44 \min$ $4.51 (2.50)$ 0.0238 $4.32 (2.64)$ 0.0006 Waderate PA W $3.0 (2.55)$ 0.0238 $4.32 (2.64)$ 0.0006 Ves $2.65 (1.60)$ 1.0622 $4.32 (2.64)$ 0.0007 Moderate PA category W $1.5 (0.49)$ $1.5 (1.2)$ $1.4 (1.67)$ Val out longer $1.6 (2.26)$ 0.0507 $4.16 (2.66)$ 0.0005 Ves $1.95 (1.63)$ 0.0507 $4.16 (2.66)$ 0.0005 Residency W W $3.30 (2.72)$ 0.1650 Residency W $0.25 (1.24)$ 0.3374 $0.75 (0.31)$ 0.0357 Residency W $0.25 (1.24)$ $0.332 (2.74)$ $0.33 (2.71)$ $0-9$ $0.5 (1.24)$ 0.3314 $0.5 (0.48)$ 0.0332 <	Gender		0.0000		0.0007
Male4.2 b (2.5)0.0027Short sleeper5.18 (1.60)<0.0005	Female	6.07 (0.55)	0.0836	4.24 (2.84)	0.8207
Shering0.000055.32 (2.59)0.00005Nort sleeper5.13 (1.77)4.35 (2.72)Walking	Male	4.25 (2.53)		4.00 (2.71)	
Shorn sleeper0.16 (1.63)40.000 (2.63)3.26 (2.59)0.0039Normal sleeper5.13 (1.77) $3.36 (2.56)$ Walking	Sleeping	0.40 (4.00)	-0.0005		0 0000
Normal sleeper 5.01 (2.43) 3.35 (2.55) Long sleeper 5.13 (1.77) 4.36 (2.72) Walking	Short sleeper	6.18 (1.60)	<0.0005	5.32 (2.59)	0.0039
	Normal sleeper	3.61 (2.43)		3.35 (2.55)	
Walking	Long sleeper	5.13 (1.77)		4.36 (2.72)	
NO2.90 (2.20)0.20623.12 (3.34)0.4469Walking4.06 (2.68)Walking2.96 (2.20)0.28283.12 (3.34)0.58231-44 min4.71 (2.28)4.41 (2.67)120 and longer3.90 (2.55)3.65 (2.74)Moderate PA	vvaiking	2.06 (2.20)	0.0082	2 12 (2 24)	0.4490
res 4.41 (2.50) 4.06 (2.68) Walking	NO Xa a	2.96 (2.20)	0.2082	3.12 (3.34)	0.4489
Waiking No walking2.96 (2.20)0.28283.12 (3.34)0.58231-44 min4.71 (2.28)4.19 (2.64)45-119 min4.68 (2.62)4.19 (2.64)Moderate PA	Yes	4.41 (2.50)		4.06 (2.68)	
No walking 2.96 (2.20) 0.2226 3.12 (3.34) 0.3525 1-44 min 4.71 (2.28) 4.41 (2.67) 139 (2.64) 0.00238 4.52 (2.64) 0.0006 Moderate PA -	vvalking	2.06 (2.20)	0.2828	2 12 (2 24)	0 5000
1-44 min4.71 (2.25)4.19 (2.04)45-119 min4.68 (2.62)3.65 (2.74)Moderate PA3.90 (2.55)3.65 (2.74)Moderate PA1.28 (1.50)0.0238Yes2.66 (1.60)1.28 (1.50)Moderate PA category1.5 (2.12)No4.52 (2.50)0.106245-119 min3.3 (1.86)1.4 (1.67)1-44 min1.75 (0.49)1.5 (2.12)45-119 min3.3 (1.86)1.4 (1.67)120 and longer1.6 (2.26)0.77 (0.99)Vigorous PAVigorous PA0.450 (2.59)0.0113Rural5.39 (2.50)0.01134.65 (2.59)0.1650Yes1.59 (2.50)0.01134.65 (2.59)0.1650Urban3.97 (2.40)3.80 (2.72)Age at symptoms0-92.85 (1.24)0.3740.75 (0.31)0.036710-194.39 (2.48)3.93 (2.71)2.23 (3.18)40-492.42250-590.00030-394.87 (2.71)5.23 (3.18)40-492.4250-590.0020-295.2 (2.22)4.41 (2.39)30-343.89 (3.14)4.16 (3.27)25-295.2 (2.22)4.41 (2.39)30-343.89 (3.14)4.16 (3.27)25-295.2 (2.22)4.41 (2.39)30-343.89 (3.14)4.16 (3.27)35-394.5 (2.09)4.81 (2.30)45-493.82 (2.30)2.68 (1.62)55-598.19.7		2.90 (2.20)	0.2828	3.12 (3.34)	0.3623
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1–44 min	4.71 (2.28)		4.19 (2.64)	
L2 and longer3.80 (2.58)3.85 (2.74)Noderate PA	45–119 min 120 and langua	4.08 (2.02)		4.41 (2.67)	
Moderate PA4.52 (2.50)0.02384.32 (2.64)0.0006Yes2.65 (1.80)1.28 (1.50)Moderate PA category1.28 (1.50)No4.52 (2.50)0.10624.32 (2.64)0.00771-44 min1.75 (0.49)1.5 (2.12)45-119 min3.3 (1.86)1.4 (1.67)1.20 and longer1.6 (2.26)0.7 (0.99)Vigorous PA $Vigorous PA$ $Vigorous PA$ 0.05074.16 (2.66)0.0065No4.43 (2.48)0.05074.16 (2.65)0.1650Urban3.97 (2.40) 3.80 (2.72)4.65 (2.59)0.1650Urban3.97 (2.40) 3.80 (2.72)4.65 (2.59)0.036710-194.39 (2.48)3.93 (2.71)0.036710-194.39 (2.48)3.93 (2.71)0.036710-194.39 (2.48)3.93 (2.71)0.036720-294.40 (2.49)4.15 (2.40)0.003230-394.87 (2.71)5.23 (3.18)0.033240-492.42250-590.000Age diagnois00010-142.35 (1.69)0.13120.55 (0.48)0.033220-244.31 (2.10)4.07 (2.91)125-295.2 (2.22)4.41 (2.39)30-343.89 (3.14)4.16 (3.27)35-394.5 (2.00)4.88 (2.30)40-443.76 (3.04)4.06 (2.77)45-493.82 (2.30)2.68 (1.62)50-548.16.750-548.16.7	120 and longer	3.90 (2.55)		3.05 (2.74)	
No4.32 (2.50)0.02384.32 (2.64)0.0006Yes2.65 (1.80)1.28 (1.50)Moderate PA category1.5 (2.12)0.00771-44 min1.75 (0.49)1.5 (2.12)45-119 min3.3 (1.86)1.4 (1.67)120 and longer1.6 (2.26)0.7 (0.99)Vigorous PA0.005074.16 (2.66)0.0065Yes1.95 (1.63)0.45 (0.53)0.0162Rural5.39 (2.50)0.01134.65 (2.59)0.1650Urban3.97 (2.40)3.80 (2.72)0.0367Age at symptoms0000-92.85 (1.24)0.33740.75 (0.31)0-92.85 (1.24)0.33740.75 (0.31)0-92.85 (1.24)0.33740.75 (0.31)0-92.85 (1.24)0.33740.75 (0.31)20-294.40 (2.49)4.15 (2.40)30-394.87 (2.71)5.23 (3.18)40-492.4220-295.2 (2.22)4.41 (2.39)30-394.87 (2.71)5.23 (3.18)20-244.31 (2.10)4.07 (2.91)25-295.2 (2.22)4.41 (2.39)30-343.89 (3.14)4.16 (3.27)35-394.5 (2.09)4.88 (2.30)40-443.76 (3.04)4.06 (2.77)35-394.5 (2.09)4.68 (2.30)40-443.76 (3.04)4.06 (2.77)45-493.82 (2.30)2.68 (1.62)50-548.16.755-598.19.760-640	Moderate PA		0.0000	4.22 (2.04)	0.0000
Tes2.50 (1.80)1.20 (1.80)Moderate PA category1.52 (1.80)No4.52 (2.50)0.10624.32 (2.64)No4.52 (2.50)0.10621.5 (2.12)45-119 min3.3 (1.86)1.4 (1.67)120 and longer1.6 (2.26)0.7 (0.99)Vigorous PA	NO	4.52 (2.50)	0.0238	4.32 (2.04)	0.0006
No4.52 (2.50)0.10624.32 (2.64)0.00771-44 min1.75 (0.49)1.5 (2.12)45-119 min3.3 (1.86)1.4 (1.67)120 and longer1.6 (2.26)0.7 (0.99)Vigorous PA	res Mederate DA seterory	2.05 (1.00)		1.26 (1.50)	
No4.32 (2.30)0.10024.32 (2.04)0.00771-44 min1.75 (0.49)1.5 (2.12)45-119 min3.3 (1.86)1.4 (1.67)120 and longer1.6 (2.26)0.7 (0.99)Vigorous PA0.50074.16 (2.66)0.0065Yes1.95 (1.63)0.45 (0.53)0.45 (0.53)Residency7777Rural5.39 (2.50)0.01134.65 (2.59)0.1650Urban3.97 (2.40)3.80 (2.72)0.33740.75 (0.31)0.036710-194.39 (2.48)3.93 (2.71)0.036710-190.036710-194.39 (2.48)3.93 (2.71)0.0367020-294.40 (2.49)4.15 (2.40)3330-394.87 (2.71)5.23 (3.18)0.033240-492.422050-590.0000Age diagnosis10-142.35 (1.69)0.13120.55 (0.48)0.033215-193.79 (2.56)3.2 (2.43)0.033215-193.79 (2.56)3.2 (2.43)20-244.31 (2.10)4.07 (2.91)25-295.2 (2.22)4.41 (2.39)30-343.89 (3.14)4.16 (3.27)35-394.5 (2.09)4.88 (2.30)40-443.76 (3.04)4.06 (2.77)4.5493.82 (2.30)2.68 (1.62)50-548.16.755-598.19.745-493.82 (2.30)2.68 (1.62)50-548.16.755-598.19.75	Noderale PA calegory	4 52 (2 50)	0 1062	4 22 (2 64)	0.0077
$\begin{array}{c c c c c c c c } 1.13 (2.12) & 1.13 (2.12) \\ 1.13 (2.12) & 1.13 (2.13) \\ 1.13 (2.12) & 1.13 (2.13) \\ 1.13 (2.13) & 1.13 (2.13) & 1.13 (2.13) \\ 1.13 (2.13) & 1.13 (2.13) & 1.13 (2.13) \\ 1.13 (2.$	1.44 min	4.52 (2.50)	0.1002	4.32 (2.04)	0.0077
$\begin{array}{cccccccc} 1.14 & 1.16 & (1.17) & (1.17) & (1.17) & (1.17) & (1.17) & (1.17) & (1.17) & (1.17) & (1.16) & (2.16) & (0.7) & (0.9) & (0.9) & (0.16) & (0.7) & (0.9) & (0.16) $	1-44 11111 45, 110 min	2.2 (1.86)		1.3 (2.12)	
Table of the second	43-119 IIIII 120 and longer	1.6 (2.26)		0.7 (0.99)	
No 4.43 (2.48) 0.0507 4.16 (2.66) 0.0065 Yes 1.95 (1.63) 0.45 (0.53) 0.45 (0.53) Rural 5.39 (2.50) 0.0113 4.65 (2.59) 0.1650 Urban 3.97 (2.40) 3.80 (2.72) Age at symptoms 0.9 2.85 (1.24) 0.3374 0.75 (0.31) 0.0367 10-19 4.39 (2.48) 3.93 (2.71) 3.93 (2.71) 0.0367 20-29 4.40 (2.49) 4.15 (2.40) 3.93 (2.71) 20-29 4.87 (2.71) 5.23 (3.18) 0.44 40-49 2.4 2 2 50-59 0.0 0 0 Age diagnosis 10-14 2.35 (1.69) 0.1312 0.55 (0.48) 0.0332 15-19 3.79 (2.56) 3.2 (2.43) 3.24 3.24 3.25 20-24 4.31 (2.10) 4.07 (2.91) 25-29 5.2 (2.22) 4.41 (2.39) 3.34 3.89 (3.14) 4.16 (3.27) 35-39 4.5 (2.09) 4.88 (2.30) 4.94 4.56 (2.77) 4.549 <t< td=""><td></td><td>1.0 (2.20)</td><td></td><td>0.7 (0.99)</td><td></td></t<>		1.0 (2.20)		0.7 (0.99)	
No 4.43 (2.40) 0.000 (0.000) 4.10 (2.00) 0.000 (0.000) Residency 0.45 (0.53) 0.45 (0.53) 0.45 (0.53) Rural 5.39 (2.50) 0.0113 4.65 (2.59) 0.1650 Urban 3.80 (2.72) 3.80 (2.72) 0.99 0.285 (1.24) 0.3374 0.75 (0.31) 0.0367 10–19 4.39 (2.48) 3.93 (2.71) 0.3367 0.0367 10–19 4.39 (2.48) 3.93 (2.71) 0.3367 20–29 4.40 (2.49) 4.15 (2.40) 3.03 (2.71) 30–39 4.87 (2.71) 5.23 (3.18) 0.0367 30–39 0.0 0 0 0 Age diagnosis 0 0 0 0 10–14 2.35 (1.69) 0.1312 0.55 (0.48) 0.0332 15–19 3.79 (2.56) 3.2 (2.43) 0 0 20–24 4.31 (2.10) 4.07 (2.91) 25-29 5.2 (2.22) 4.41 (2.39) 3.03 3.03 3.03 3.03 3.45 (2.09) 4.88 (2.30)	No	1 13 (2 18)	0.0507	4 16 (2 66)	0.0065
Test Test (1.50) 0.40 (0.53) Residency	Ves	1.95 (1.63)	0.0307	0.45 (0.53)	0.0003
Rural $5.39 (2.50)$ 0.0113 $4.65 (2.59)$ 0.1650 Urban $3.97 (2.40)$ $3.80 (2.72)$ Age at symptoms -9 $2.85 (1.24)$ 0.3374 $0.75 (0.31)$ 0.0367 $10-19$ $4.39 (2.48)$ $3.93 (2.71)$ $0.232 (3.18)$ $0.232 (3.18)$ $20-29$ $4.40 (2.49)$ $4.15 (2.40)$ $0.23 (3.18)$ $40-49$ 2.4 2 2 $50-59$ 0.0 0 0 Age diagnosis $10-14$ $2.35 (1.69)$ 0.1312 $0.55 (0.48)$ 0.0332 $15-19$ $3.79 (2.56)$ $3.2 (2.43)$ 0.0332 $20-24$ $4.31 (2.10)$ $4.07 (2.91)$ $2.52.92$ $2.2 (2.2)$ $4.41 (2.39)$ $3.93 (3.14)$ $4.16 (3.27)$ $35-39$ $4.5 (2.09)$ $4.88 (2.30)$ $40-44$ $3.76 (3.04)$ $4.06 (2.77)$ $45-49$ $3.82 (2.30)$ $2.68 (1.62)$ $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	Residency	1.00 (1.00)		0.40 (0.00)	
Initial 0.00 (2.00) 0.00 (2.00) 0.00 (2.00) Age at symptoms 0-9 2.85 (1.24) 0.3374 0.75 (0.31) 0.0367 10-19 4.39 (2.48) 3.93 (2.71) 0.200 0 20-29 4.40 (2.49) 4.15 (2.40) 3.03 (2.71) 0.0367 30-39 4.87 (2.71) 5.23 (3.18) 0.0332 40-49 2.4 2 2 50-59 0.0 0 0 Age diagnosis 10-14 2.35 (1.69) 0.1312 0.55 (0.48) 0.0332 15-19 3.79 (2.56) 3.2 (2.43) 0.0332 0 0 20-24 4.31 (2.10) 4.07 (2.91) 25-29 5.2 (2.22) 4.41 (2.39) 0.332 30-34 3.89 (3.14) 4.16 (3.27) 35-39 4.5 (2.09) 4.88 (2.30) 0 40-44 3.76 (3.04) 4.06 (2.77) 4.54 6.7 55-59 8.1 9.7 60-64 0 0 0 0	Bural	5 39 (2 50)	0 0113	4 65 (2 59)	0 1650
Age at symptoms 0.000 (2.1.2) 0-9 2.85 (1.24) 0.3374 0.75 (0.31) 0.0367 10-19 4.39 (2.48) 3.93 (2.71) 2029 4.40 (2.49) 4.15 (2.40) 30-39 4.87 (2.71) 5.23 (3.18) 2 2 50-59 0.0 0 0 Age diagnosis 0.00 0 0 10-14 2.35 (1.69) 0.1312 0.55 (0.48) 0.0332 15-19 3.79 (2.56) 3.2 (2.43) 0.0332 20-24 4.31 (2.10) 4.07 (2.91) 25-29 25-29 5.2 (2.22) 4.41 (2.39) 30-34 30-34 3.89 (3.14) 4.16 (3.27) 35-39 30-34 3.89 (3.14) 4.16 (3.27) 35-39 35-39 4.5 (2.09) 4.88 (2.30) 4.406 (2.77) 45-49 3.82 (2.30) 2.68 (1.62) 50-54 50-54 8.1 6.7 55-59 55-59 8.1 9.7 60-64 0	Urban	3 97 (2 40)	0.0110	3 80 (2.72)	0.1000
Age are provided and the second sec	Age at symptoms	0.01 (2.40)		0.00 (2.72)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 <u>-9</u>	2 85 (1 24)	0.3374	0.75 (0.31)	0 0367
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	10–19	4 39 (2 48)	0.001	3 93 (2 71)	
30-39 $4.87 (2.71)$ $5.23 (3.18)$ $40-49$ 2.4 2 $50-59$ 0.0 0 Age diagnosis 0.1312 $0.55 (0.48)$ 0.0332 $15-19$ $3.79 (2.56)$ $3.2 (2.43)$ $20-24$ $4.31 (2.10)$ $4.07 (2.91)$ $25-29$ $5.2 (2.22)$ $4.41 (2.39)$ $30-34$ $3.89 (3.14)$ $4.16 (3.27)$ $35-39$ $4.5 (2.09)$ $4.88 (2.30)$ $40-44$ $3.76 (3.04)$ $4.06 (2.77)$ $45-49$ $3.82 (2.30)$ $2.68 (1.62)$ $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	20–29	4 40 (2 49)		4 15 (2 40)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	30–39	4.87 (2.71)		5.23 (3.18)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	40-49	2.4		2	
Age diagnosis0.13120.55 (0.48)0.0332 $10-14$ $2.35 (1.69)$ 0.1312 $0.55 (0.48)$ 0.0332 $15-19$ $3.79 (2.56)$ $3.2 (2.43)$ $20-24$ $4.31 (2.10)$ $4.07 (2.91)$ $25-29$ $5.2 (2.22)$ $4.41 (2.39)$ $30-34$ $3.89 (3.14)$ $4.16 (3.27)$ $35-39$ $4.5 (2.09)$ $4.88 (2.30)$ $40-44$ $3.76 (3.04)$ $4.06 (2.77)$ $45-49$ $3.82 (2.30)$ $2.68 (1.62)$ $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	50–59	0.0		0	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Age diagnosis				
15-19 $3.79(2.56)$ $3.2(2.43)$ $20-24$ $4.31(2.10)$ $4.07(2.91)$ $25-29$ $5.2(2.22)$ $4.41(2.39)$ $30-34$ $3.89(3.14)$ $4.16(3.27)$ $35-39$ $4.5(2.09)$ $4.88(2.30)$ $40-44$ $3.76(3.04)$ $4.06(2.77)$ $45-49$ $3.82(2.30)$ $2.68(1.62)$ $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	10–14	2.35 (1.69)	0.1312	0.55 (0.48)	0.0332
20-24 $4.31(2.10)$ $4.07(2.91)$ $25-29$ $5.2(2.22)$ $4.41(2.39)$ $30-34$ $3.89(3.14)$ $4.16(3.27)$ $35-39$ $4.5(2.09)$ $4.88(2.30)$ $40-44$ $3.76(3.04)$ $4.06(2.77)$ $45-49$ $3.82(2.30)$ $2.68(1.62)$ $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	15–19	3.79 (2.56)		3.2 (2.43)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	20–24	4.31 (2.10)		4.07 (2.91)	
30-34 $3.89 (3.14)$ $4.16 (3.27)$ $35-39$ $4.5 (2.09)$ $4.88 (2.30)$ $40-44$ $3.76 (3.04)$ $4.06 (2.77)$ $45-49$ $3.82 (2.30)$ $2.68 (1.62)$ $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	25–29	5.2 (2.22)		4.41 (2.39)	
35-39 4.5 (2.09) 4.88 (2.30) $40-44$ 3.76 (3.04) 4.06 (2.77) $45-49$ 3.82 (2.30) 2.68 (1.62) $50-54$ 8.1 6.7 $55-59$ 8.1 9.7 $60-64$ 0 0	30–34	3.89 (3.14)		4.16 (3.27)	
40-443.76 (3.04)4.06 (2.77)45-493.82 (2.30)2.68 (1.62)50-548.16.755-598.19.760-6400	35–39	4.5 (2.09)		4.88 (2.30)	
45-493.82 (2.30)2.68 (1.62)50-548.16.755-598.19.760-6400	40–44	3.76 (3.04)		4.06 (2.77)	
50-54 8.1 6.7 55-59 8.1 9.7 60-64 0 0	45–49	3.82 (2.30)		2.68 (1.62)	
55-598.19.760-6400	50–54	8.1		6.7	
60–64 0 0	55–59	8.1		9.7	
	60–64	0		0	

Table 3: Disease severity and function of patients with ankylosing spondylitis (BASDAI)

BASDAI: The Bath Ankylosing Spondylitis Disease Activity Index, BASFI: The Bath Ankylosing Spondylitis Functional Index, PA: Physical activity, The bold numbers show the significant differences.

possible reason for this late diagnosis could be the misdiagnosis or incorrect diagnosis by clinicians. The delay in diagnosis put the patients at a higher risk of disease severity and function. In this study, the patients who were diagnosed lately had worse disease severity and function in this region. Therefore, it is important to diagnose the disease as much as at the early stages. The duration of disease diagnosis is different based on the geographic areas.^{9,11,16} Patients with AS consult a

different group of health-care providers due to having extra-articular manifestations of AS from primary care physicians to orthopedic surgeons, to different medical and surgical specialists. The patients may receive unnecessary and often invasive investigations resulting in a delay in diagnosis.¹⁸ A study conducted in India reported that the main factors contributing to delay in diagnosis are incorrect diagnosis as non-specific back, degenerative disc disease, rheumatoid arthritis, and

Medical information (n=101)	Disease severity (BASADI)		Disease functio	Disease function (BASFI)	
	Mean (SD)	Р	Mean (SD)	Р	
Peripheral arthritis					
No	3.50 (2.39)	0.0027	3.08 (2.25)	0.0019	
Yes	4.98 (2.40)		4.74 (2.81)		
Sacroiliitis					
None	2.73 (2.23)	0.1734	4.3 (2.59)	0.8459	
Unilateral	3.1 (1.82)		3.2 (3.15)		
Bilateral	4.48 (2.50)		4.03 (2.72)		
Tenosynovitis					
No	4.24 (2.51)	0.3489	3.89 (2.61)	0.2687	
Yes	4.89 (2.41)		4.73 (3.17)		
Plantar fasciitis					
No	4.09 (2.63)	0.2764	3.71 (2.57)	0.2138	
Yes	4.63 (2.32)		4.38 (2.84)		
Achilles tendinitis					
No	4.49 (2.52)	0.1903	4.17 (2.6)	0.0042	
Yes	3.63 (2.29)		2.13 (1.52)		
Anterior uveitis					
No	4.36 (2.54)	0.8445	4.04 (2.70)	0.8957	
Yes	4.25 (2.40)		3.95 (2.75)		
HLA-B27					
No	5.79 (2.62)	0.1270	5.55 (2.55)	0.2240	
Not done	3.82 (2.44)		4.07 (2.46)		
Yes	4.41 (2.46)		3.79 (2.82)		
Spinal involvement					
No	1.08 (0.96	0.0008	1.37 (1.89	0.0125	
Yes	4.54 (2.42		4.19 (2.67		
Treatment					
No treatment	5.33 (2.41)	0.5950	5.13 (3.30)	0.3250	
Biological	4.03 (2.57)		4.03 (2.67)		
Non-steroidal	4.8 (2.53)		4.64 (2.39)		
Physical therapy	3.8		0.30		
Multi-therapy	4.45 (2.43)		3.61 (2.53)		

Table 4: Disease severity of patients with medical information in patients ankylosing spondylitis (BASADI)

BASDAI: The Bath Ankylosing Spondylitis Disease Activity Index, BASFI: The Bath Ankylosing Spondylitis Functional Index, HLA: Human leukocyte antigen, SD: Standard deviation, The bold numbers show the significant differences.

Table 5: Controlling factors to function ofpatients with ankylosing spondylitis

Outcome: Disease function (BASFI)	Ρ
	0.00001
	0.19774
	0.20871
	0.40510
	0.47454
	0.49153
	0.62191
	0.86773
	0.99829
	Outcome: Disease function (BASFI)

Standard least square with effect leverage was performed for statistical analyses. The red bold number shows the predictor. BASDAI: The Bath Ankylosing Spondylitis Disease Activity Index, BASFI: The Bath Ankylosing Spondylitis Functional Index, PA: Physical activity

tuberculosis of the spine. This incorrect diagnosis results in prolonged receiving time by patients. Furthermore, the absence of extra-articular manifestations and juvenile age substantially relayed to diagnostic delay.¹⁸ In agreement with the findings in our study,¹⁸ reported that diagnostic delay is substantially associated with worse disease severity and function as measured by BASDAI and BASFI. The most initial incorrect diagnoses were confirmed among orthopedics (75.9%), followed by general physicians (50%), and rheumatologists (12%). Therefore, the health-care providers need continuous education courses for the correct diagnosis of inflammatory back pain may assist in the early diagnosis of AS.

The disease severity and function of our patients in this region were worse compared to the patients in other regions.^{7,19} Living in rural areas, short sleeping, and spinal involvement were predictors of disease severity and indirectly disease function in this study. The patients who live in rural areas have less opportunity for follow-up services since we have only one center of rheumatologic disease in the Duhok governorate. The spinal involvement may back to the effects of the treatment or late diagnosis of the disease. The spinal involvement may back to the effects of AS in patients.





Figure 1: Controlling factors to function of patients with ankylosing spondylitis



Figure 2: Controlling factors to disease severity in patients with ankylosing spondylitis

The higher prevalence of juvenile-onset and extraarticular manifestations in the form of uveitis, dactylitis, and enthesitis in patients with peripheral arthritis may have a role in further pathogenies. The patients with peripheral arthritis (more than half of the patients in our study) may have had an aggressive form of the disease as indicated by higher ESR levels, worse spinal indices, higher frequency of enthesitis, and more common whole spine involvement.¹⁹

Limitations of the study

The strong point of this study is that we tried to include as many as possible the patients who were registered in the center. Only a few patients were missed from this study

Table 6: Controlling factors to disease severityin patients with ankylosing spondylitis

Outcome: Disease severity (BASDAI)	Ρ
	0.00023
	0.00307
	0.00648
	0.05431
	0.06357
	0.12913
	0.18802
	0.35491
	0.40070
	0.56336
	0.64254
	0.70478
	0.71043
	0.82460
	0.84749
	0.89279
	Outcome: Disease severity (BASDAI)

Standard least square with effect leverage was performed for statistical analyses. The red bold numbers show the predictors. BASDAI: The Bath Ankylosing Spondylitis Disease Activity Index, PA: Physical activity, HLA: Human leukocyte antigen

as they were not available despite contacting them several times. This is a cross-sectional study limiting us to make a causal pathway for the disease severity and function. However, it gives a good picture of the prevalence of extra-articular manifestations of AS and the association of disease severity and function with sociomedical information. This gives us a golden way of the management of these patients.

CONCLUSION

This study showed that the scores of disease severity and function of patients with AS are high in this region. The disease of the patients was diagnosed lately. The disease severity and function were associated with healthy lifestyles such as sleeping and physical activity. Living in rural areas, short sleeping, and spinal involvement were predictors of disease severity in patients with AS.

ACKNOWLEDGMENTS

The authors of the study would like to present deep thanks to the patients and administration of the "Specialized centre of rheumatic diseases and medical rehabilitation" in Duhok city in Kurdistan Region. In addition, we would like to present deep thanks and gratitude to Mr Deldar Morad Abdulah for statistical calculations and critical review of the manuscript.

REFERENCES

- Zochling J and Braun J. Management and treatment of ankylosing spondylitis. Curr Opin Rheumatol. 2005;17(4):418-425. https://doi.org/10.1097/01.bor.0000163194.48723.64
- Carron P, Van Praet L and Van den Bosch F. Peripheral manifestations in spondyloarthritis: Relevance for diagnosis, classification and follow-up. Curr Opin Rheumatol. 2012;24(4):370-374.

https://doi.org/10.1097/BOR.0b013e32835448de

- Stolwijk C, Essers I, Van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: A population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373-1378. https://doi.org/10.1136/annrheumdis-2014-205253
- Momeni M, Taylor N and Tehrani M. Cardiopulmonary manifestations of ankylosing spondylitis. Int J Rheumatol. 2011;11(5):728471.
- Sieper J, Braun J, Rudwaleit M, Boonen A and Zink A. Ankylosing spondylitis: An overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8-iii18.

https://doi.org/10.1136/ard.61.suppl_3.iii8

6. Braun J and Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-1390.

https://doi.org/10.1016/S0140-6736(07)60635-7

- Alam F, Lutf AQ, Abdulla N, Elsayed EH and Hammoudeh M. Characteristics of ankylosing spondylitis patients living in qatar. Egypt Rheumatol. 2017;39(2):103-108.
- Al-Arfaj A. Profile of ankylosing spondylitis in Saudi Arabia. Clin Rheumatol. 1996;15(3):287-289. https://doi.org/10.1007/BF02229709
- Al-Qadi R, Salih SF, AlDoski HJ, Nabeel M, Ali JH, Khasho D, et al. Association of HLA-B* 27 with ankylosing spondylitis in Kurdish patients. Int J Rheum Dis. 2017;20(8):980-984. https://doi.org/10.1111/1756-185X.12605
- 10. Otom A and Al-Ahmar M. HLA-B27 and ankylosing spondylitis in Jordan. Global Adv Res J Med Med Sci. 2013;252-255.
- Nazarinia MA, Ghaffarpasand F, Heiran HR and Habibagahi Z. Pattern of ankylosing spondylitis in an Iranian population of 98 patients. Mod Rheumatol. 2009;19(3):309-315. https://doi.org/10.1007/s10165-009-0153-5
- Jassim N and Majeed S. The assessment of knowledge in sample of iraqi patients with ankylosing spondylitis. Rheumatology (Bulgaria). 2020;28(1):31-40.
- Rudwaleit M, Van Der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (Part II): Validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.
 - https://doi.org/10.1136/ard.2009.108233
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P and Calin A. A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286-2291.
- Calin A, Garrett S, Whitelock H, Kennedy LG, O'hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21(12):2281-2285.
- Tayel M, Soliman E, El Baz W, El Labaan A, Hamaad Y and Ahmed M. Registry of the clinical characteristics of spondyloarthritis in a cohort of Egyptian population. Rheumatol

Asian Journal of Medical Sciences | Nov 2022 | Vol 13 | Issue 11

Int. 2012;32(9):2837-2842.

https://doi.org/10.1007/s00296-011-2068-7

 Baek H, Shin K, Lee Y, Kang S, Lee E, Yoo C, et al. Clinical features of adult-onset ankylosing spondylitis in Korean patients: Patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD. Rheumatology (Oxford). 2004;43(12):1526-1531.

https://doi.org/10.1093/rheumatology/keh373

- Aggarwal R and Malaviya AN. Diagnosis delay in patients with ankylosing spondylitis: Factors and outcomes-an Indian perspective. Clin Rheumatol. 2009;28(3):327-331. https://doi.org/10.1007/s10067-008-1049-z
- Aggarwal R and Malaviya AN. Clinical characteristics of patients with ankylosing spondylitis in India. Clin Rheumatol. 2009;28(10):1199-1205.

https://doi.org/10.1007/s10067-009-1227-7

Authors Contribution:

Mahir Sadullah Saeed- Concept and design of the study, data collection, review, preparing the first draft, and analysis; Mohammed Tahir Rasool- Concept of the study, review, analysis, and final approval.

Work attributed to:

Specialized Centre of Rheumatic Diseases and Medical Rehabilitation; Duhok General Directorate of Health, Kurdistan 42001, Dihok, Iraq.

Orcid ID:

Dr. Mahir Sadullah Saeed - D https://orcid.org/0000-0002-3964-0422

Source of Funding: None, Conflicts of Interest: None.